Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.
Company Growth (employees)
Cambridge, US
Size (employees)
90 (est)+43%
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics Office Locations

Akebia Therapeutics has office in Cambridge
Cambridge, US

Akebia Therapeutics Metrics

Akebia Therapeutics Summary

Market capitalization

$165.4 m

Closing share price

Akebia Therapeutics's current market capitalization is $165.4 m.

Akebia Therapeutics Market Value History

We estimate that Akebia Therapeutics's current employees are approximately 24% female and 76% male.

Akebia Therapeutics Job Categories

Akebia Therapeutics Online Presence

Akebia Therapeutics Company Life

You may also be interested in